PSA screening for prostate cancer: The current controversy

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1293-1296

  De Koning, H J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Evidence; Mortality; Prostate cancer; PSA; Screening; Side effects

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; HIGH RISK POPULATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

CARCINOMA; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; MORTALITY; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUEBEC; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032431173     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008428327309     Document Type: Review

References (4)

1. NCR (Netherlands Cancer Registry). Incidence of Cancer in the Netherlands, 1994. Utrecht: SIG Healthcare Information 1997.
2. van Oortmarssen GJ, Habbema JDF. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative Pap smears. Int J Epidemiol 1995; 24: 300-7.
3. van Oortmarssen GJ, Boer R, Habbema JDF. Modelling issues in cancer screening. Stat Meth Med Res 1995; 4: 33-54.
4. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94.